Skip to main content

Advertisement

SpringerLink
Log in

Genetic causes of Parkinson’s disease: UCHL-1

  • Review
  • Published:
Cell and Tissue Research Aims and scope Submit manuscript

Abstract

The ubiquitin proteasome system is an important cellular pathway that ubiquitinates damaged proteins and degrades them via the 26S proteasome. Abnormalities of this pathway can result in molecular protein aggregation and have been associated with Parkinson’s disease (PD). UCHL-1, an enzyme central to the system, possesses catalytic hydrolase activity that can hydrolyze peptide-ubiquitin bonds and recycle ubiquitin monomers for re-use in the same process. Recently, UCHL-1 has been shown to possess a second dimerisation-dependent ligase activity and, at least in vitro, this ligase activity promotes alpha synuclein aggregation. UCHL-1 was first implicated in PD by the discovery of an I93M mutation identified in a German sib-pair with probable autosomal dominant PD. Although no further UCHL-1 mutations have been identified, a common non-synonymous S18Y polymorphism has been suggested to reduce disease susceptibility in non-mendelian forms of PD. In vitro functional data support this protective effect, with evidence that S18Y possesses reduced ligase activity compared with wild type UCHL-1. One study has found increased hydrolase activity associated with S18Y, although another study has not. Important issues regarding UCHL-1 and its role in PD remain inconclusive, especially regarding the pathogenicity of the mendelian I93M mutation. This review tries to address some of these uncertainties.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Choi J, Levey AI, Weintraub ST, Rees HD, Gearing M, Chin LS, Lian L (2004) Oxidative modifications and downregulation of ubiquitin carboxy-terminal hydrolase L1 associated with idiopathic Parkinson’s and Alzheimer’s diseases. J Biol Chem 13:13256–13264

    Google Scholar 

  • Ciechanover A, Orian A, Schwartz AL (2000) The ubiquitin mediated proteolytic pathway: mode of action and clinical implications. J Cell Biochem 34(Suppl):40–51

    Google Scholar 

  • Couzin J (2002) Human genome. HapMap launched with pledges of $100 million. Science 298:941–942

    CAS  PubMed  Google Scholar 

  • Dauer W, Przedborski S (2003) Parkinson’s disease: mechanisms and models. Neuron 39:889–909

    Article  CAS  PubMed  Google Scholar 

  • Dawson TM, Dawson VL (2003) Molecular pathways of neurodegeneration in Parkinson’s disease. Science 302:819–822

    Article  CAS  PubMed  Google Scholar 

  • Elbaz A, Levecque C, Clavel J, Vidal JS, Richard F, Correze JR, Delemotte B, Amouyel P, Alperovitch A, Chartier-Harlin MC, Tzourio C (2003) S18Y polymorphism in the UCH-L1 gene and Parkinson’s disease: evidence for an age-dependent relationship. Mov Disord 18:130–137

    Article  PubMed  Google Scholar 

  • Goldstein DB, Ahmadi KR, Weale ME, Wood NW (2003) Genome scans and candidate gene approaches in the study of common diseases and variable drug responses. Trends Genet 19:615–622

    Google Scholar 

  • Harhangi BS, Farrer MJ, Lincoln S, Bonifati V, Meco G, De Michele G, Brice A, Durr A, Martinez M, Gasser T, Bereznai B, Vaughan JR, Wood NW, Hardy J, Oostra BA, Breteler MM (1999) The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson’s disease. Neurosci Lett 270:1–4

    PubMed  Google Scholar 

  • Hershko A, Ciechanover A (1998) The ubiquitin system. Annu Rev Biochem 67:425–479

    CAS  PubMed  Google Scholar 

  • Hochstrasser M (1996a) Protein degradation or regulation: Ub the judge. Cell 84:813–815

    Article  CAS  PubMed  Google Scholar 

  • Hochstrasser M (1996b) Ubiquitin-dependent protein degradation. Annu Rev Genet 30:405–439

    CAS  PubMed  Google Scholar 

  • Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608

    CAS  PubMed  Google Scholar 

  • Kruger R, Eberhardt O, Riess O, Schulz JB (2002) Parkinson’s disease: one biochemical pathway to fit all genes? Trends Mol Med 8:236–240

    Article  CAS  PubMed  Google Scholar 

  • Leroy E, Boyer R, Auburger G, Leube B, Ulm G, Mezey E, Harta G, Brownstein MJ, Jonnalagada S, Chernova T, Dehejia A, Lavedan C, Gasser T, Steinbach PJ, Wilkinson KD, Polymeropoulos MH (1998) The ubiquitin pathway in Parkinson’s disease. Nature 395:451–452

    CAS  PubMed  Google Scholar 

  • Levecque C, Destee A, Mouroux V, Becquet E, Defebvre L, Amouyel P, Chartier-Harlin MC (2001) No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson’s disease. J Neural Transm 108:979–984

    Article  CAS  PubMed  Google Scholar 

  • Lincoln S, Vaughan J, Wood N, Baker M, Adamson J, Gwinn-Hardy K, Lynch T, Hardy J, Farrer M (1999) Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson’s disease. Neuroreport 5:427–429

    Google Scholar 

  • Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury PT Jr (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson’s disease susceptibility. Cell 111:209–218

    Article  CAS  PubMed  Google Scholar 

  • Liu Y, Lashuel HA, Choi S, Xing X, Case A, Ni J, Yeh LA, Cuny GD, Stein RL, Lansbury PT Jr (2003) Discovery of inhibitors that elucidate the role of UCH-L1 activity in the H1299 lung cancer cell line. Chem Biol 10:837–846

    Article  CAS  PubMed  Google Scholar 

  • Lowe J, McDermott H, Landon M, Mayer RJ, Wilkinson KD (1990) Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol 16:153–160

    Google Scholar 

  • Maraganore DM, Farrer MJ, Hardy JA, Lincoln SJ, McDonnell SK, Rocca WA (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson’s disease. Neurology 53:1858–1860

    CAS  PubMed  Google Scholar 

  • Maraganore DM, Lesnick TG, Elbaz A, Chartier-Harlin MC, Gasser T, Kruger R, Hattori N, Mellick GD, Quattrone A, Satoh J, Toda T, Wang J, Ioannidis JP, De Andrade M, Rocca WA (2004) UCHL1 is a Parkinson’s disease susceptibility gene. Ann Neurol 55:512–521

    Article  PubMed  Google Scholar 

  • McNaught KS, Jenner P (2001) Proteasomal function is impaired in the substantia in Parkinson’s disease. Neurosci Lett 297:191–194

    CAS  PubMed  Google Scholar 

  • McNaught KS, Bjorklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW (2002a) Proteasome inhibition causes nigral degeneration with inclusion bodies in rats. Neuroreport 13:1437–1441

    Article  CAS  PubMed  Google Scholar 

  • McNaught KS, Mytilineou C, Jonbaptiste R, Yabut J, Shashidharan P, Jennert P, Olanow CW (2002b) Impairment of the ubiquitin-proteasome system causes dopaminergic cell death and inclusion body formation in ventral mesencephalic cultures. J Neurochem 81:301–306

    CAS  PubMed  Google Scholar 

  • Mellick GD, Silburn PA (2000) The ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism does not confer protection against idiopathic Parkinson’s disease. Neurosci Lett 293:127–130

    Article  CAS  PubMed  Google Scholar 

  • Momose Y, Murata M, Kobayashi K, Tachikawa M, Nakabayashi Y, Kanazawa I, Toda T (2002) Association studies of multiple candidate genes for Parkinson’s disease using single nucleotide polymorphisms. Ann Neurol 51:133–136

    Article  CAS  PubMed  Google Scholar 

  • Nishikawa K, Li H, Kawamura R, Osaka H, Wang YL, Hara Y, Hirokawa T, Manago Y, Amano T, Noda M, Aoki S, Wada K (2003) Alterations of structure and hydrolase activity of parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem Biophys Res Commun 304:176–183

    Article  CAS  PubMed  Google Scholar 

  • Osaka H, Wang YL, Takada K, Takizawa S, Setsuie R, Li H, Sato Y, Nishikawa K, Sun YJ, Sakurai M, Harada T, Hara Y, Kimura I, Chiba S, Namikawa K, Kiyama H, Noda M, Aoki S, Wada K (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum Mol Genet 12:1945–1958

    Article  CAS  PubMed  Google Scholar 

  • Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 276:2045–2047

    CAS  PubMed  Google Scholar 

  • Rideout HJ, Larsen KE, Sulzer D, Stefanis L (2001) Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J Neurochem 78:899–908

    Article  CAS  PubMed  Google Scholar 

  • Saigoh K, Wang YL, Suh JG, Yamanishi T, Sakai Y, Kiyosawa H, Harada T, Ichihara N, Wakana S, Kikuchi T, Wada K (1999) Intragenic deletion in the gene encoding ubiquitin carboxy-terminal hydrolase in gad mice. Nat Genet 23:47–51

    CAS  PubMed  Google Scholar 

  • Satoh J, Kuroda Y (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson’s disease in a Japanese population. J Neurol Sci 189:113–117

    Article  CAS  PubMed  Google Scholar 

  • Savettieri G, De Marco EV, Civitelli D, Salemi G, Nicoletti G, Annesi G, Ciro Candiano IC, Quattrone A (2001) Lack of association between ubiquitin carboxy-terminal hydrolase L1 gene polymorphism and PD. Neurology 57:560–561

    CAS  PubMed  Google Scholar 

  • Shi Q, Tao E (2003) An Ile93Met substitution in the UCH-L1 gene is not a disease-causing mutation for idiopathic Parkinson’s disease. Chin Med J (Engl) 116:312–313

    Google Scholar 

  • Solano SM, Miller DW, Augood SJ, Young AB, Penney JB Jr (2000) Expression of alpha-synuclein, parkin, and ubiquitin carboxy-terminal hydrolase L1 mRNA in human brain: genes associated with familial Parkinson’s disease. Ann Neurol 47:201–210

    CAS  PubMed  Google Scholar 

  • Spillantini M, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M (1997) Alpha synuclein in Lewy bodies. Nature 388:839–840

    CAS  PubMed  Google Scholar 

  • Voges D, Zwickl P, Baumeister W (1999) The 26S proteasome: a molecular machine designed for controlled proteolysis. Annu Rev Biochem 68:1015–1068

    CAS  PubMed  Google Scholar 

  • Wang J, Zhao CY, Si YM, Liu ZL, Chen B, Yu L (2002) ACT and UCH-L1 polymorphisms in Parkinson’s disease and age of onset. Mov Disord 17:767–771

    Article  PubMed  Google Scholar 

  • Weissman AM (2001) Themes and variations on ubiquitination. Nat Rev Mol Cell Biol 2:169–178

    Article  CAS  PubMed  Google Scholar 

  • Wilkinson KD, Hochstrasser M (1998) The deubiquitinating enzyme. In: Peters JM, Harris JR, Finley D (eds) Ubiquitin and the biology of the cell. Plenum, New York, pp 99–125

  • Wintermeyer P, Kruger R, Kuhn W, Muller T, Woitalla D, Berg D, Becker G, Leroy E, Polymeropoulos M, Berger K, Przuntek H, Schols L, Epplen JT, Riess O (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson’s disease patients. Neuroreport 11:2079–2082

    CAS  PubMed  Google Scholar 

  • Zhang J, Hattori N, Leroy E, Morris HR, Kubo S, Kobayashi T, Wood NW, Polymeropoulos MH, Mizuno Y (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson’s disease. Parkinsonism Relat Disord 6:195–197

    Article  PubMed  Google Scholar 

Download references

We are grateful to Dr. Miratul M. Muqit, for advice and comments during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Molecular Neuroscience, Institute of Neurology, Queen Square, London, WC1N 3BG, UK

    Daniel G. Healy, Patrick M. Abou-Sleiman & Nicholas W. Wood

Authors
  1. Daniel G. Healy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrick M. Abou-Sleiman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas W. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel G. Healy.

Additional information

D.G.H. is a clinical research fellow at the Institute of Neurology, Queen Square and is supported by a grant from the UK Parkinson’s Disease Society (grant no. 4073). P.A.S. is supported by a grant from the Brain Research Trust (grant no. 6AAC). N.W.W. is supported by the UK Parkinson’s Disease Society (grant no. 4029)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Healy, D.G., Abou-Sleiman, P.M. & Wood, N.W. Genetic causes of Parkinson’s disease: UCHL-1 . Cell Tissue Res 318, 189–194 (2004). https://doi.org/10.1007/s00441-004-0917-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00441-004-0917-3

Keywords

Search

Navigation